Tritium-labeled 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 was administered by intravenous injection into humans. The initial half-life in plasma was determined to be about 3 min. About 35% of the injected radioactivity was excreted in the urine and about 55% in the feces. Twenty-three urinary metabolites were identified. The metabolites included beta-oxidized and omega-oxidized products as well as metabolites in which the 9-methylene group had been biotransformed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
9-deoxo-1616-dimethyl-9-methylene prostaglandin
8
metabolism 9-deoxo-1616-dimethyl-9-methylene
4
prostaglandin humans
4
humans tritium-labeled
4
tritium-labeled 9-deoxo-1616-dimethyl-9-methylene
4
prostaglandin administered
4
administered intravenous
4
intravenous injection
4
injection humans
4
humans initial
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!